Monopar Therapeutics Inc
NASDAQ:MNPR

Watchlist Manager
Monopar Therapeutics Inc Logo
Monopar Therapeutics Inc
NASDAQ:MNPR
Watchlist
Price: 25.82 USD 8.53% Market Closed
Market Cap: 136.3m USD
Have any thoughts about
Monopar Therapeutics Inc?
Write Note

Monopar Therapeutics Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Monopar Therapeutics Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Monopar Therapeutics Inc
NASDAQ:MNPR
Selling, General & Administrative
-$2.9m
CAGR 3-Years
-4%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
-5%
CAGR 5-Years
-15%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.6B
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7.5B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.5B
CAGR 3-Years
-22%
CAGR 5-Years
-19%
CAGR 10-Years
-17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$2.9B
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-21%
No Stocks Found

Monopar Therapeutics Inc
Glance View

Market Cap
136.3m USD
Industry
Biotechnology

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.

MNPR Intrinsic Value
18.25 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Monopar Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-2.9m USD

Based on the financial report for Sep 30, 2024, Monopar Therapeutics Inc's Selling, General & Administrative amounts to -2.9m USD.

What is Monopar Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-6%

Over the last year, the Selling, General & Administrative growth was 9%. The average annual Selling, General & Administrative growth rates for Monopar Therapeutics Inc have been -4% over the past three years , -6% over the past five years .

Back to Top